The burgeoning field of weight management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These novel therapies represent a significant departure from traditional GLP-3 receptor agonists, exhibiting improved efficacy in promoting meaningful weight shedding and improving … Read More

Emerging in the arena of obesity treatment, retatrutide represents a unique approach. Different from many existing medications, retatrutide functions as a double agonist, simultaneously affecting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) sensors. The concurrent activation fosters several advantageous effects, … Read More